LUND, Sweden, July 22, 2022 /PRNewswire/ — Cantargia AB (publ) (“Cantargia” or the “Company”) (Nasdaq Stockholm: CANTA) publishes prospectus and certain new financial information in connection with the rights issue that was resolved by the board of directors on 21 June 2022 and that was approved by an extraordinary general meeting on 21 July 2022 (the “Rights Issue”).
The prospectus relating to the Rights Issue has today been approved and registered by the Swedish Financial Supervisory Authority and is available on Cantargia’s website, www.cantargia.com, as well as on Carnegie Investment Bank AB’s (publ) website, www.carnegie.se. The prospectus will also be available on the Swedish Financial Supervisory Authority’s website, www.fi.se.
New financial information included in the prospectus
The prospectus contains certain financial information regarding Cantargias’s capitalization and net indebtedness as of 31 May 2022 that has not previously been published. The new financial information is presented in the tables below. The information has not been reviewed by the Company’s auditor.
Capitalization
Legal reserve(s) corresponds to Share premium account as of 31 May 2022.
Other reserves consist of MSEK -891.4 in Balanced Loss, MSEK -182.8 in Result of the Year and MSEK 14.7 in Employee Option Program as of 31 May 2022.
Net indebtedness
Other current financial assets include short-term investments at banks and in fixed income funds.
Current financial liabilities (including debt instruments, but excluding current portion of non-current financial liabilities) reflects amounts as of 31 May 2022 corresponding to the line items “Trade payables”, “Tax liabilities”, “Other liabilities” and “Accrued expenses and deferred income”.
Timetable for the Rights Issue
Record date for the Rights Issue, 25 July 2022.
Trading in subscription rights, 27 July 2022 – 5 August 2022.
Subscription period, 27 July 2022 – 10 August 2022.
Trading in paid subscribed shares (BTAs), 27 July 2022 – 11 August 2022.
Announcement of the outcome of the Rights Issue, around 12 August 2022.
Advisers
In conjunction with the Rights Issue, the Company has engaged Barclays Bank Ireland PLC and Carnegie Investment Bank AB (publ) as Joint Global Coordinators and Bookrunners. Advokatfirman Vinge acts as legal counsel to the Company and Baker & McKenzie Advokatbyrå KB acts as legal counsel to the Joint Global Bookrunners.
This information was submitted for publication, through the agency of the contact person set forth below, at 14.15 CEST on 22 July 2022.
For further information, please contact:
Göran Forsberg, CEO
Mobile: +46 (0)46-275 62 60
-E-mail: goran.forsberg@cantargia.com
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main project, the antibody nadunolimab, is being studied clinically in combination with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.
About nadunolimab (CAN04)
The antibody CAN04 binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1a and IL-1ß signaling. Thereby, CAN04 can counteract the contribution of the IL-1 system to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. CAN04 is investigated in multiple ongoing clinical trials. In the phase I/IIa study CANFOUR, first line combination therapy is investigated with standard chemotherapies in patients with PDAC (gemcitabine/nab-paclitaxel) and patients with NSCLC (cisplatin/gemcitabine) (NCT03267316). Positive interim data for the combination therapies show durable responses in 73 patients with PDAC, resulting in median iPFS of 7.2 months and median survival of 12.7 months. Stronger efficacy was also observed in 30 NSCLC patients with median PFS of 6.8 months. A response rate of 53 percent was achieved, with even higher responses in non-squamous NSCLC patients previously treated with pembrolizumab. These results show stronger efficacy than expected from chemotherapy alone. CAN04 is investigated with chemotherapy also in the phase I study CAPAFOUR, with the FOLFIRINOX regimen for first line treatment of metastatic PDAC (NCT04990037), and in two further clinical studies, CESTAFOUR (NCT05116891) and TRIFOUR (NCT05181462), in additional forms of cancer, including biliary tract cancer, colorectal cancer and triple negative breast cancer. CAN04 is also evaluated with the immune checkpoint inhibitor pembrolizumab, with or without chemotherapy, in the phase I study CIRIFOUR (NCT04452214).
Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade with shares or other securities in Cantargia. No action has been taken and measures will not be taken to permit a public offering in any other jurisdictions besides Sweden.
This press release is not a prospectus according to the definition in Regulation (EU) 2017/2019 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. This press release neither identifies nor pretends to identify risks (direct or indirect) that can be connected to an investment in shares or other securities in Cantargia. A prospectus will be prepared in connection with the Rights Issue and be reviewed and approved by the Swedish Financial Supervisory Authority, which is the national competent authority in Sweden with regard to the Prospectus Regulation. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the prospectus. Thus, investors are encouraged to review the prospectus in its entirety.
The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to the United States of America, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such act would be unlawful, where such action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities law. No shares or other securities in Cantargia have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (“Securities Act”) or the securities legislation of any state or other jurisdiction in the United States of America and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.
(CONTINUA)